SELECTBIO Clinical Translation of Stem Cells 2014 brings together basic scientists, clinician-scientists, as well as medical practitioners/surgeons focusing on studying, characterizing, and deploying various classes of stem cells for therapeutic utility.
In addition to top-tier presentations during this conference, SELECTBIO has also partnered with surgeons and surgery centers in the Palm Springs area to offer conference delegates a “hands-on” Clinical Practicum providing conference delegates the ability to observe in real-time adipose tissue extraction and processing ex vivo. This “hands-on” demonstration led by leading surgeons in the field is in full compliance with applicable laws and regulations and performed by board-certified surgeons.
This conference therefore provides valuable learning and networking experiences for both basic researchers and clinicians alike seeking the most up-to-date information, protocols, and products in this emerging field.
All delegates are automatically registered to the Clinical Practicum which will be conducted in the evening after the conclusion of the conference presentations.
David Stipp has written about science, medicine, the environment and biotech since 1982 for The Wall Street Journal, Fortune, Salon, Science and other publications. He led Fortune's science and medical coverage from 1995 to 2005 as a senior writer, and from 1982 to 1995 covered science and medicine as a staff reporter at The Wall Street Journal. Over the past decade he has written extensively on the science of aging, and during his career he has also covered, among other things, the Pentagon's growing concern about the risk of abrupt climate change, the application of Darwin to medicine, childhood lead poisoning, new treatments for impotence, animal intelligence, and the effects of birth order on personality. In 1998 he won a National Association of Science Writer's award for best magazine article, and in 1993-4 served as a Knight Fellow at the Massachusetts Institute of Technology.
From the pages of Scientific American comes the latest information and explorations into the futuristic world of biotechnology.
-Recent breakthroughs in human longevity and life extension
-Tissue engineering and the regeneration of limbs and organs
-Biochemistry, from transgenic crops to biological warfare
-The results and ramifications of the Human Genome Project
-The current and future state of cloning and artificial wombs
-Radical biotech: head transplants, artificial intelligence, and virtual senses
The 21st century will undoubtedly witness unprecedented advances in understanding the mechanisms of the human body and in developing biotechnology. With the mapping of the human genome, the pace of discovery is now on the fast track. By the middle of the century we can expect that the rapid progress in biology and biotechnology will utterly transform human life. What was once the stuff of science fiction may now be within reach in the not-too-distant future: 20-to-40-year leaps in average life spans, enhanced human bodies, drugs and therapies to boost memory and speed up mental processing, and a genetic science that allows parents to ensure that their children will have stronger immune systems, more athletic bodies, and cleverer brains. Even the prospect of human immortality beckons.
Such scenarios excite many people and frighten or appall many others. Already biotechnology opponents are organizing political movements aimed at restricting scientific research, banning the development and commercialization of various products and technologies, and limiting citizens’ access to the fruits of the biotech revolution.
BIOCOMP is an international conference that serves researchers, scholars, professionals, students, and academicians who are looking to both foster working relationships and gain access to the latest research results. It is being held jointly (same location and dates) with a number of other research conferences; namely, The 2013 World Congress in Computer Science, Computer Engineering, and Applied Computing (WORLDCOMP). The Congress is the largest annual gathering of researchers in computer science, computer engineering and applied computing. We anticipate to have 2,100 or more attendees from over 85 countries.
Andrew Hessel is a futurist and catalyst in biological technologies, helping industry, academics, and authorities better understand the changes ahead in life science. He is a Distinguished Researcher with Autodesk Inc.’s Bio/Nano Programmable Matter group, based out of San Francisco. He is also the co-founder of the Pink Army Cooperative, the world’s first cooperative biotechnology company, which is aiming to make open source viral therapies for cancer.
Trained in microbiology and genetics, Andrew has continually worked at the forefront of genomics, first to read and comprehend bacterial, human, and other genomes and more recently to write them. He believes the technology that makes this possible, called synthetic biology, is revolutionary and that it will eventually surpass information technology (IT) as an economic engine and driver of societal change. He speaks widely on topics that include cells as living computers, life science as an emerging IT industry, and biological safety and security.
Andrew is an advocate of open genetic engineering, believing that the field will increasingly resemble the software industry and give rise to open source, single purpose (app), and ‘freemium’ applications, and that it will be spearheaded by younger programmer-entrepreneurs. He is active in the iGEM and DIYbio (do-it-yourself) communities and frequently works with students and young entrepreneurs to help them be successful. Since 2009, Andrew has also been the co-chair of Bioinformatics and Biotechnology at the Singularity University, located at the NASA Research Park in Mountain View, California. There, he educates graduate students and executive participants on the disruptive shifts underway in life science and helps them become actively engaged in these changes. In November, 2011, he was appointed a fellow at the University of Ottawa, Institute for Science, Society, and Policy, focusing on how next-generation technologies shape society’s future.
Andrew has given dozens of invited talks related to synthetic biology, for groups that include Autodesk Inc., the FBI, the United Nations Biological Weapons Convention Implementation Support Unit, TEDx, Intel Inc., the New America Foundation, Alberta Innovates Technology Futures, the Oil Sands Leadership Initiative, and Statoil.